Format

Send to

Choose Destination
See comment in PubMed Commons below
Annu Rev Pharmacol Toxicol. 2014;54:9-26. doi: 10.1146/annurev-pharmtox-011613-135943. Epub 2013 Aug 30.

The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.

Author information

  • 1Department of Neuroscience and Uppsala Biomedical Center, Uppsala University, 75124 Uppsala, Sweden; email: helgi.schioth@neuro.uu.se.

Abstract

The largest innovations within pharmaceutical development come through new compounds that have unique and novel modes of action. These innovations commonly involve expanding the protein space targeted by pharmaceutical agents. At present, information about drugs and drug targets is available online via public databases such as DrugBank and the Therapeutic Targets Database. However, this information is biased, understandably so, toward established drugs and drug-target interactions. To gain a better overview of the drug-targeted portion of the human proteome and the directions of current drug development, we developed a data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind. Our curation identified 475 potentially novel clinical trial drug targets. This review aims to identify trends in drug development based on the potentially novel targets currently being explored in clinical trials.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center